NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









UroMems

UroMems

Private
EybensHealthcare & Life Scienceshttps://www.uromems.com/

Last Round

Strategic

May 13, 2026

Total Funding Raised

$168.27M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

UroMems is a medical device company that specializes in the design, development, and commercialization of active implantable devices for the treatment of stress urinary incontinence.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Keywords

artificial urinary sphinctersmart implanturological devicestress urinary incontinencebioelectronic medicinepelvic floor disorderimplantable medical deviceclinical trialmedtechurology techactive implantFDA IDEinvestigational device exemptionsmart urology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

UroMems Comparables

Compare UroMems with similar companies based on industry and business-model similarity.

UroMems comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Affluent Medical
90%
Rigicon, Inc.
84%
Zephyr Surgical Implants
82%

UroMems Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMay 13, 2026
Series CJun 25, 2024
GrantNov 13, 2023
Series BApr 20, 2021
Series BMay 20, 2020
Series A
Nov 15, 2016

Key People

Founding team and executive leadership

Pierre Mozer

Chief Medical Officer (Co-Founder)

Founding Team

Hamid Lamraoui

CEO

Executive Team

Agnès Dimey

CFO

Executive Team

John Murphy

Chief Operating Officer

Executive Team

UroMems Investors

Notable investors and investment history

UroMems investors
InvestorRounds
European Innovation Council FundSeries C
European Commission (Horizon Europe)Series C
Ajax HealthStrategic
Montpensier ArbevelSeries C, Series B
Banque PopulaireSeries B
BpifranceSeries A, Series B, Grant, Series C
Supernova InvestSeries B, Series C, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 13, 2026

    $60M round led by Ajax Health

  • Feb 17, 2026

    Expanding US presence for clinical evaluations.

UroMems Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

UroMems Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about UroMems's valuation, stock price, and market status.

Firmographic Details

HeadquartersEybens
Employee Range89
Year Founded2011
Last FundingMay 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.